Validation of AML-Score in older adults receiving daunorubicin/cytarabine liposome intensive induction chemotherapy for treatment of secondary acute myeloid leukemia.

被引：0
|
作者：
Schmucker, Abigail
Leiby, Benjamin
Wilde, Lindsay
机构：
[1] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e19000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19000
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia
    Liu, Jiazhuo
    Mi, Yingchang
    Fu, Mingwei
    Yu, Wenjuan
    Wang, Ying
    Lin, Dong
    Bian, Shougeng
    Wang, Jianxiang
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (07) : 422 - 427
  • [22] Severity of and contributors to distress in patients with acute myeloid leukemia (AML) receiving induction chemotherapy
    LeBlanc, Thomas William
    Wolf, Steven Paul
    Davis, Debra M.
    Samsa, Greg
    Locke, Susan C.
    El-Jawahri, Areej
    Tulsky, James A.
    Abernethy, Amy P.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29)
  • [23] Inpatient Geriatric Assessment Detects Impairment Among Older Adults Receiving Induction Chemotherapy for Acute Myelogenous Leukemia.
    Klepin, Heidi D.
    Geiger, Ann M.
    Williamson, Jeff
    Kritchevsky, Stephen
    Tooze, Janet A.
    Ellis, Leslie Renee
    Levitan, Denise
    Isom, Scott
    Powell, Bayard L.
    BLOOD, 2009, 114 (22) : 570 - 571
  • [24] Geriatric Assessment Predicts Overall Survival Among Older Adults Receiving Induction Chemotherapy for Acute Myelogenous Leukemia.
    Klepin, Heidi D.
    Tooze, Janet A.
    Geiger, Ann M.
    Kritchevsky, Stephen
    Williamson, Jeff
    Ellis, Leslie R.
    Levitan, Denise
    Pardee, Timothy
    Isom, Scott
    Powell, Bayard L.
    BLOOD, 2010, 116 (21) : 653 - 654
  • [25] Decision criteria for the futility of intensive chemotherapy in older patients with acute myeloid leukemia (AML)
    Dombrel, Herve
    Malfuson, Jean-Valere
    Etienne, Anne
    Turlure, Pascal
    de Revel, Thierry
    Thomas, Xavier
    Contentin, Nathalie
    Terre, Christine
    Michallet, Mauricette
    Castaigne, Sylvie
    Bordessoule, Dominique
    Vey, Norbert
    Gardin, Claude
    BLOOD, 2007, 110 (11) : 841A - 842A
  • [26] Quality of life and coping in adult patients with acute myeloid leukemia (AML) receiving intensive chemotherapy
    Schumacher, A
    Wewers, D
    Büchner, T
    Berdel, WE
    PSYCHO-ONCOLOGY, 2000, 9 (05) : S58 - S58
  • [27] The important role of intensive induction chemotherapy in the treatment of acute myeloid leukemia
    Lin, Tara L.
    Pagano, Livio
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (03) : 303 - 313
  • [28] LITHIUM TREATMENT IN ADULTS WITH ACUTE MYELOID-LEUKEMIA RECEIVING CHEMOTHERAPY
    HORNS, RC
    SCHRIER, SL
    GREENBERG, PL
    MEDICAL AND PEDIATRIC ONCOLOGY, 1984, 12 (03): : 169 - 172
  • [29] Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML)
    Stone, Richard M.
    DeAngelo, Daniel J.
    Letai, Anthony G.
    Stewart, Jeremy M.
    McGinnis, Michael
    Brown, Francis
    Fell, Geoffrey
    Flammand, Yael
    Konopleva, Marina
    Garcia, Jacqueline S.
    Luskin, Marlise R.
    BLOOD, 2020, 136
  • [30] Alliance A041701-a Randomized Phase 2/3 Study of Conventional Chemotherapy plus /- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy
    Uy, Geoffrey L.
    Yin, Jun
    Klepin, Heidi D.
    Dinner, Shira
    Jaslowski, Anthony J.
    Strickland, Stephen A.
    Liesveld, Jane L.
    Byrd, John C.
    Stone, Richard M.
    BLOOD, 2019, 134
12345